In Japan, ROS1 fusion gene testing has been covered by insurance since 2017, and BRAF V600E mutation testing since 2018, but they were hardly investigated in lung cancer cases from 2008 to 2014 when our patients were enrolled. This evidence concerns the gene BRAF and lung carcinoma.